Artikel
Reduction of heart failure in streptozotocin-induced diabetic rats after p38 MAPK inhibition
Verminderung der Diabetes-mellitus-bedingten Herzinsuffizienz nach Inhibition der p38 MAP-Kinase
Suche in Medline nach
Autoren
Veröffentlicht: | 11. November 2004 |
---|
Gliederung
Text
p38 Mitogen-activated protein kinase (p38 MAPK) is one of the most ancient intracellular signaling molecules and is involved in multiple cellular processes, including cell growth, cell proliferation and apoptosis.
Many factors/stresses are known to activate the p38 MAPK. One of them is hyperglycemia.
In the heart, enhanced activation of p38 MAPK is associated with ischemia and/or reperfusion injury and the onset of heart failure.
To investigate the possible functional role of p38 MAPK during the development of diabetes mellitus-induced heart failure we measured cardiac/haemodynamic parameters in streptozotocin (STZ) induced diabetic rats treated with the selective p38 MAPK inhibitor (p38-I) SB 239063.
Experiments were performed in STZ-induced diabetic Sprague Dawley (SD) rats treated with p38-I (70mg/kg/day;p.o.) or vehicle and in age matched controls (n=9/group).
6 weeks after STZ injection haemodynamic parameters for systolic (LVP, dP/dtmax) and diastolic function (LVEDP, dP/dtmin, Tau) and HR were studied in anaesthetized animals using a 2F Millar-tip-catheter inserted in the left ventricle via the right carotid artery.
LV function between normoglycemic SD and SD/p38-I did not differ. As expected SD/STZ animals developed an impaired LV function indicated by a reduction in LVP (64.6±1.7 vs. 101.3±1.7; [mmHg], p<0.05) and dP/dtmax (2606.18±228.1 vs. 4373.33±162;[mmHg/sec], p<0.05) as well as an increase in dP/dtmin (-1998.74±159.1 vs. -3900.1±121.7;[mmHg/sec], p<0.05), Tau (22.8±2.2 vs. 14.9±0.7;[ms], p<0.05) and LVEDP (9.88±0.7 vs. 4.02±0.4; [mmHg], p<0.05) compared to normoglycemic controls.
LV function of SD/STZ/p38-I rats was significantly improved compared to SD/STZ animals (LVP 75.7±1.8; dP/dtmax 3626.9±176; dP/dtmin -2931±126; Tau 18.7±1.4).
Thus, we conclude that inhibition of p38 MAPK may provide a protective effect for the heart under STZ-diabetic conditions.